FDA Clearance Tracker · P160048-S031
Eversense® Continuous Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 19, 2026
Approved
Time to decision
24 days
Received Feb 23, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160048-S031
- Device name
- Eversense® Continuous Glucose Monitoring System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Feb 23, 2026
- Decided
- Mar 19, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS) protocol.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense AP CGM SystemNew device typeDe Novo
DEN230052 · Decided Apr 29, 2024 · 264 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring (CGM) SystemPMA supplement
P160048-S021 · Decided Mar 29, 2023 · 180 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.